Citations

Clear

382 citation(s) found for "Shapiro, CL".

Redefining Evidence‐Based Practice Through Patient Values: A Theoretical Innovation for Person‐Centered, Value‐Based Care
Shapiro, S , Logvinov, Ilana I. , Thomas, Rachel McMahan , Shapiro, Sandra D , Logvinov, Ilana

Mayo Clinic

Journal of Evaluation in Clinical Practice | January 22, 2026 | Volume: 32 | Issue: 1 | Pages: No page available

10.1111/jep.70344 | PMID 41569875 Get It

ABSTRACT Rationale Before evidence‐based practice (EBP) was formally adopted, healthcare decisions relied on critical thinking and clinical judgment informed by disciplinary knowledge, theory, and research, but lacked full integration of patient values with clinical expertise. Sackett et al. redefined EBP as the integration of the best available evidence, clinical expertise, and patient values. This framework has been embraced by nursing and other healthcare disciplines, embedding EBP into education, clinical protocols, and quality improvement efforts. Despite widespread adoption, traditional conceptualizations prioritize empirical evidence above patient values, potentially undermining individualized care. Aims and Objectives This paper proposes a reconceptualization that places patient and client values—their why —at the center of EBP, inspired by Simon Sinek's Golden Circle model which emphasizes starting with purpose to influence behavior effectively. Prioritizing the patient's values before incorporating empirical evidence into a care plan ensures that care aligns with their personal goals and definitions of health, fostering therapeutic relationships and supporting meaningful behavior change. Methods A conceptual analysis was conducted using Simon Sinek's Golden Circle model as a guiding framework. This model emphasizes starting with purpose to influence behavior effectively. The analysis explores how integrating patient values first, followed by empirical evidence and clinical expertise, can operationalize person‐centered EBP. Results The reconceptualized framework positions patient values as the foundation of care planning. By aligning interventions with patients' personal goals and values first, clinicians can strengthen therapeutic relationships and support individualized care. Conclusion Effective nursing clinicians and leaders must embrace this patient‐first approach to truly operationalize person‐centered, evidence‐based care that respects the diverse needs and motivations of patients.
Medical management of inflammatory bowel diseases
Limdi, Jimmy K. , Shapiro, Jason M. , Shah, Samir A. , Hashash, Jana G.

Mayo Clinic

BMJ | December 19, 2025 | Volume: 391 | Issue: No issue available | Pages: e079050

10.1136/bmj-2025-079050 | PMID 41419296 Get It

Abstract Inflammatory bowel diseases (IBD), comprising Crohn’s disease and ulcerative colitis, are chronic, inflammatory, immune mediated, relapsing-remitting conditions of the gastrointestinal tract with multidimensional and often negative effects on patients’ quality of life. The global burden of IBD is increasing and is forecast to affect 1% of the population in early industrialized nations over the next 10 years. Advances in our understanding of the causes and pathogenesis of IBD in the past three decades have translated into new treatments that modulate the immune inflammatory cascade. Modern goals of treatment are clinical remission through assessment of patient reported outcomes and deep remission defined as mucosal healing on colonoscopy or imaging. Achieving both clinical and deep remission affords patients a better long term prognosis and quality of life. This review summarizes the latest evidence on IBD diagnosis, staging, and prognosis, with a detailed focus on current treatments.
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on Group A Streptococcal Pharyngitis: Risk Assessment Using Clinical Scoring Systems in Children and Adults
Linder, Jeffrey A. , Watson, Michael E. , Wessels, Michael R. , Carter, Danielle M, Cohen, Adam L. , Bard, Jennifer Dien , Erdem, Güliz , Gregory, Christopher J. , Mochon, A. Brian, Kaur, Dipleen, Barshak, Miriam B. , Barshak, Miriam B , Kourtis, Athena P. , Martin, Judith M. , Shapiro, Daniel J. , Stevens, Ryan W.

Mayo Clinic

Clinical Infectious Diseases | December 3, 2025 | Volume: 82 | Issue: Supplement_3 | Pages: i97-i104

10.1093/cid/ciaf668 | PMID 41343363 Get It

Abstract This publication represents the first part of an update to the clinical practice guideline on the diagnosis and management of group A streptococcal (Streptococcus pyogenes or GAS) pharyngitis, developed by the Infectious Diseases Society of America (IDSA). Diagnosis of GAS pharyngitis by clinician judgment alone is unreliable, and unselective testing incurs cost and inconvenience for individuals at low risk of having GAS infection. Clinical scoring systems have been used to quantify the probability of a positive GAS throat culture based on standardized criteria such as the presence of fever; tonsillar enlargement or exudate; tender and enlarged anterior cervical lymph nodes; and the absence of cough. The goal of this article is to determine whether a scoring system should be used to decide which patients should have a diagnostic test performed by rapid antigen detection test, molecular methods, and/or throat culture. We performed a systematic review of randomized and nonrandomized studies that compared the use of a clinical scoring system to clinician judgment alone in predicting the outcome of a throat culture. Evidence from studies in children and adults suggests the diagnostic accuracy of a clinical scoring system is comparable to or slightly higher than clinician judgment alone. However, the studies are limited due to small size, lack of uniformity in outcome measures, and incomplete data. The consensus of the panel is that the balance of benefits and harms favors use of a clinical scoring system as part of the evaluation of patients with sore throat. The principal utility of using a scoring system is to identify patients with low probability of GAS pharyngitis and to reduce unnecessary testing.
Patient Characteristics and Outcomes of Cardiac Rehabilitation Following Thoracic Aortic Dissection Surgery: A Multicenter Retrospective Study
Heybati, Kiyan , Ochal, Domenic, Poudel, Keshav , Zuberi, Eric , Deng, Jiawen , Dineen, Elizabeth H. , Brahmbhatt, Pavan M., Daugherty, David H., Farres, Sam, Landolfo, Kevin, Bonikowske, Amanda R. , Mergo, Patricia J. , Shapiro, Brian P. , Deng, J , Taylor, Bryan J. , Brahmbhatt, Pavan M., Landolfo, Kevin , Thomas, Randal J.

Mayo Clinic

Journal of Cardiopulmonary Rehabilitation and Prevention | November 26, 2025 | Volume: 46 | Issue: 1 | Pages: 50-57

10.1097/hcr.0000000000000982 | PMID 41294921 Get It

Purpose: Despite the 2022 American Heart Association/American College of Cardiology guidelines recommending cardiac rehabilitation (CR) after aortic dissection repair, both patient participation in CR and the associated clinical outcomes remain poorly understood. Methods: Adults (≥18 years of age) discharged alive following thoracic aortic dissection surgery across the Mayo Clinic Enterprise (January 2012 to November 2022), with follow-up until May 2024, were included (IRB #24-001141). Data were presented using summary statistics and logistic regression modeling. Results: A total of 186 patients were referred; 37% were female, and the median age was 64 (51, 73) years. Dissections were classified as type A (43%), type B (18%), or a combination, and 55% had residual dissection. Over half (53%) did not start CR, with older age (aOR = 0.97: 95% CI, 0.94 - 0.99; P = .003), family history of aortic dissections and/or aneurysms (aOR = 0.17: 95% CI, 0.04 - 0.54; P = .005), and tobacco use (aOR = 0.35: 95% CI, 0.13 - 0.91; P = .037) being associated with lower odds of enrollment. Of the 87 who enrolled, 34 did so at a Mayo Clinic facility. There were no complications, with no difference in adverse outcomes. Among those with evaluations at graduation from CR (n = 21), quality of life (Dartmouth index 16 [14, 19] vs 25 [22, 30]; P = .002) and 6-minute walk distance (488 [375, 531] vs 302 [235, 398] m; P = .001) improved. Conclusions: Following thoracic aortic dissection repair, CR significantly improved quality of life and functional capacity without adverse events. Further work is needed to improve enrollment and establish data-driven safety margins for exercise.
Regulation of Immune Function by CD22 on Antigen-Presenting Cells 3071
Zastrow, Alexi, Crotts, Sydney B. , Maniaci, Brandon Lee, Chen, Yin , Lillemon, Katie, Collett, Chris, Friedman, David J. , Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.910 Get It

Abstract Description Interactions between ST6GAL1-produced sialic acids and Siglec-2 (CD22) result in immune inactivation. CD22 is a well-characterized regulator of B cell function. We demonstrate that conventional type-2 dendritic cells (cDC2s) and hybrid macrophages express CD22 across the spleen and tumor microenvironment. To understand the function of CD22 on antigen-presenting cells, we generated novel CD22-floxed mice and crossed them with a) Zbtb46-Cre ones (those lacking CD22 on cDC2s and hybrid macrophages) as well as b) CX3CR1-Cre mice (without CD22 on hybrid macrophages nor microglia). From the former cross, we generated subcutaneous flank tumor and colitis-associated colorectal cancer models. CD22 expression on myeloid cells did not impact anti-tumor responses when tumors expressed low CD22 ligand levels. From here, we assess the impact of tumor cell CD22 ligand overexpression on tumor responses. Also, to evaluate CD8 T cell response to CD22, we challenged mice with Theiler’s murine encephalomyelitis virus (TMEV), modeling multiple sclerosis via CD8 T cell hyperactivation. CD22 did not mediate CD8 activation nor infiltration in brains of the latter cross. Thus, CD22 may be functionally redundant across myeloid and B cells. Topic Categories Innate Immune Responses and Host Defense: Cellular Mechanisms (INC)
Siglec-E functions as a brake for intestinal inflammation to protect from colitis-associated cancer 3022
Maniaci, Brandon Lee, Crotts, Sydney B. , Zastrow, Alexi, Martinez, Kodi, Rajcula, Matthew, Lillemon, Katie, Collett, Chris, Friedman, David, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.865 Get It

Abstract Description The lifetime risk for colorectal cancer in the United States is approximately 4%. Individuals with Inflammatory Bowel Disease, including Ulcerative Colitis and Crohn’s Disease, have a substantially increased risk of developing colorectal cancer. The mechanisms for accelerated tumorigenesis due to enhanced inflammation are not fully characterized. Siglecs (sialic acid immunoglobulin lectin-like proteins) are a family of inhibitory receptors that are negative regulators of the immune response. Siglec-E is an inhibitory receptor that is expressed by innate immune cells, including monocytes, macrophages, neutrophils, and dendritic cells. Interestingly, mice deficient in Siglec-E have accelerated the development of tumors and reduced survival in a spontaneous mouse model of colorectal cancer (TS4-cre LSL-KRasG12D APClox468/wt). Siglec-E knockout mice also have accelerated gut inflammation using the DSS colitis model as compared to WT mice. Using the DSS/AOM model of colitis-associated colorectal cancer, we found that Siglec-E KO mice develop more tumors as compared to wild-type controls. Thus, Siglec-E is an important regulator of gut homeostasis, and the loss of Siglec-E accelerates colon cancer in two murine models. Funding Sources Mayo Clinic Center for Biomedical Discovery NIH R01 CA243545-01A1 to VSS T32 AI170478 Mayo Clinic Graduate School of Biomedical Sciences Deans fellowship: Initiative for maximizing student development (IMSD) R25 GM055252-26 Doyon Foundation Topic Categories Mucosal and Regional Immunology (MUC)
Defining the role of HDAC3 enzymatic vs. adaptor function in T cells 3044
Martinez, Kodi, Shapiro, Michael J. , Chen, Maggie, Choe, Justin, Crotts, Sydney, Maniaci, Brandon, Zastrow, Alexi, Barnes, Jackson, Carlson, Abby, Shapiro, Michael, Lillemon, Katie, Collett, Chris, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.884 Get It

Abstract Description Generation of T cells requires dynamic epigenetic alteration of histones to control gene expression at each developmental stage. The Class I deacetylases HDAC1, HDAC2, and HDAC3 have been shown to have 3 functions: adaptor, decrotonylase, and deacetylase activity. The relative importance of each function in T cells is not known. CD2icre HDAC3 cKO mice develop severe colitis and demonstrate that HDAC3 is required during thymocyte development for positive selection, DP survival, and CD4 lineage commitment. Recently, a mutation was identified in HDAC3 that eradicated deacetylase activity (“VRPP”). We generated a novel mouse model with Cre-mediated deletion of endogenous HDAC3 and linked re-expression of HDAC3 VRPP, which maintained adaptor function but lacks both deacetylase and decrotonylase enzymatic activity. Similar to CD2icre HDAC3 cKO mice, HDAC3 VRPP mice have a block in positive selection due to failure to down regulate RORγt and decreased DP cell survival due to increased expression of P2RX7, demonstrating that HDAC3 enzymatic activity is required for these functions. However, when the positive selection defect is bypassed in HDAC3 VRPP mice, CD4+ lineage commitment is restored. Strikingly, this mouse does not develop spontaneous colitis even up to one year of age, although T cell development is still impaired. Thus, there are different roles for HDAC3 enzymatic vs. adaptor function during T cell development which are made evident in HDAC3 VRPP mice. Funding Sources NIAID RO1 AI150100; T32 AI170478; Mayo Clinic Graduate School of Biomedical Sciences Topic Categories Lymphocyte Differentiation and Peripheral Maintenance (LYM)
ST8Sia6 regulates TNF signaling and CCL5-mediated immune cell migration to restrain inflammatory bowel disease 4245
Crotts, Sydney B. , Barnes, Jackson, Antonetti, Regina, Shapiro, Michael J. , Lillemon, Kathryn, Collett, Christian, Barnes, Jackson, Shapiro, Michael, Collett, Christian, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.1950 Get It

Abstract Description Inflammatory bowel disease (IBD) affects between 1-3 million people in the United States, and patients present with symptoms including diarrhea, rectal bleeding, and fatigue. ST8Sia6 is a sialic acid transferase that adds terminal a2,8 disialic acids to O-linked glycoproteins, and a SNP in ST8Sia6 is associated with Crohn’s Disease. We have found that ST8Sia6 knockout (KO) and heterozygous (het) mice exhibit a 30-fold increase in small bowel immune infiltrate, along with an increased proportion of Th1 and pathogenic Th17 CD4 cells. These mice also exhibit activated gut epithelia, increased inflammatory cytokines, and increased innate cell activation, indicative of gut inflammation. Both ST8Sia6 KO and het mice exhibit increased weight loss and decreased survival when challenged with low dose dextran sodium sulfate-induced colitis. CellChat pathway analysis demonstrates enhanced TNF and IL-1 pathway activation in ST8Sia6 KO small bowel epithelium as compared to WT mice. In addition, ST8Sia6 KO small bowel epithelium produces significantly more CCL5, which may drive immune cell migration. These data demonstrate a role for ST8Sia6 in regulating gut immune homeostasis. As TNF blockade is a first line therapy for IBD patients, elucidating the role of ST8Sia6 in regulating this pathway is critical for a mechanistic understanding of IBD pathogenesis, and this may help to improve immunotherapy options for the disease. Funding Sources NIH R01CA243545 & NIH 5T32DK124190 Topic Categories Basic Autoimmunity (BA)
Regulation of anti-tumor immunity by B7-H3 binding to Siglec-9 4287
Chen, Yin , Medlyn, Michael J. , Shapiro, M., Huynh, Truc, Crotts, Sydney B. , Zastrow, Alexi, Billadeau, Daniel D. , Shapiro, Michael J., Kimball, Brooke , Huynh, Truc , Kenderian, Saad S. , Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.1987 Get It

Abstract Description B7-H3 is a member of the B7 superfamily, which includes co-inhibitory receptors such as B7-H1/PD-L1 and co-stimulatory receptors such as B7-1/CD80 and B7-2/CD86. B7-H3 is upregulated by almost all types of tumors and is associated with worse prognosis. However, the exact mechanism by which B7-H3 suppresses anti-tumor immune response remains to be discovered as its ligand has yet to be identified. Sialic acid modifications are also increased in many cancers and are similarly associated with poor outcome. Here, we demonstrate for the first time that sialylated B7-H3 binds to the immune inhibitory receptor Siglec-9. Siglec-9 is expressed on many immune cells, including NK cells and T cells. We have shown that B7-H3 expression on target cells reduces killing by Siglec-9 expressing NK cells in vitro. We then hypothesized that antibodies that block B7-H3 binding to Siglec-9 will be an effective intervention to boost anti-tumor immunity. We have generated a high affinity anti-B7-H3 monoclonal antibody, F7, which blocks B7-H3 binding to Siglec-9. F7 functions to enhance NK cell killing of B7-H3 expressing target cells in vitro. F7 also dramatically enhances CART19 mediated killing of B7-H3 expressing Nalm6 cells in a relapse model in NSG mice in vivo. In summary, our work has demonstrated that B7-H3 binds Siglec-9, and blockade of such interaction can enhance anti-tumor immunity. Funding Sources • Mayo Clinic Center for Biomedical Discovery • NIH Glycobiology Common Fund supplement to R01CA243545-01A1 to VSS Topic Categories Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)
The nutrient-sensing Rag-GTPase complex in B cells controls humoral immunity via TFEB/TFE3-dependent mitochondrial fitness 2091
Wu, Yue , Li, Yanfeng , Sun, Jie , Zhu, Xingxing , Zhou, Xian , Shapiro, Virginia Smith , Sun, Jie , Boothby, Mark Robin , Zeng, Hu

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.055 Get It

Abstract Description During the humoral immune response, B cells undergo rapid metabolic reprogramming with a high demand for nutrients, which are vital to sustain the formation of the germinal centers (GCs). Rag-GTPases sense amino acid availability to modulate the mechanistic target of rapamycin complex 1 (mTORC1) pathway and suppress transcription factor EB (TFEB) and transcription factor enhancer 3 (TFE3). However, how Rag-GTPases coordinate amino acid sensing, mTORC1 activation, and TFEB/TFE3 activity in humoral immunity remains undefined. Here, we show that B cell-intrinsic Rag-GTPases are critical for the development and activation of B cells. RagA/RagB deficient B cells fail to form GCs, produce antibodies, and generate plasmablasts in both T-dependent (TD) and T-independent (TI) humoral immune responses. Deletion of RagA/RagB in GC B cells leads to abnormal dark zone (DZ) to light zone (LZ) ratio and reduced affinity maturation. Mechanistically, the Rag-GTPase complex constrains TFEB/TFE3 activity to prevent mitophagy dysregulation and maintain mitochondrial fitness in B cells, which are independent of canonical mTORC1 activation. TFEB/TFE3 deletion restores B cell development, GC formation in Peyer’s patches and TI humoral immunity, but not TD humoral immunity in the absence of Rag-GTPases. Collectively, our data establish Rag-GTPase-TFEB/TFE3 pathway as an mTORC1 independent mechanism to coordinating nutrient sensing and mitochondrial metabolism in B cells. Funding Sources National Institute of Allergy and Infectious Diseases (NIAID) - AI162678 National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) - AR077518 Topic Categories Immune Response Regulation: Molecular Mechanisms (IRM)